Finance

Lists
Q2 2027 earnings
See results
SPARC:NSE
Sun Pharma Advanced Research Co Ltd
₹193.78
-1.21%
(-2.38) 1D
Nov 6, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for SPARC...
Open
₹195.00
High
₹196.72
Low
₹189.85
Mkt. cap
62.78B
Avg. vol.
962.34K
Volume
873.51K
P/E ratio
3.96
52-wk high
₹289.00
52-wk low
₹108.00
EPS
₹48.91
Shares outstanding
255.99M
No. of employees
279
Open
₹195.00
High
₹196.72
Low
₹189.85
Mkt. cap
62.78B
Avg. vol.
962.34K
Volume
873.51K
P/E ratio
3.96
52-wk high
₹289.00
52-wk low
₹108.00
EPS
₹48.91
Shares outstanding
255.99M
No. of employees
279
News stories
From web sources and news partners
About Sun Pharma Advanced Research Co Ltd
CEO-
Employees279
Founded2006
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitesparc.life
Last report
Nov 2, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
536.50M / -
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
84.50M
18.53B
399.20M
536.50M
Cost of goods sold
72.10M
115.06M
76.60M
99.50M
Cost of revenue
72.10M
115.06M
76.60M
99.50M
Research and development expenses
62.70M
28.44M
132.60M
92.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
424.60M
557.37M
448.00M
448.50M
Operating expense
604.50M
605.33M
684.60M
678.90M
Total operating expenses
676.60M
720.39M
761.20M
778.40M
Operating income
-592.10M
17.81B
-362.00M
-241.90M
Other non operating income
-
-116.03M
236.60M
-
EBT including unusual items
-803.50M
17.61B
-206.70M
-243.10M
EBT excluding unusual items
-679.90M
17.61B
-206.70M
-243.10M
Income tax expense
700.00K
-3.84M
1.10M
800.00K
Effective tax rate
-0.09%
-0.02%
-0.53%
-0.33%
Other operating expenses
91.50M
-3.44M
82.00M
115.90M
Net income
-804.20M
17.61B
-207.80M
-243.90M
Net profit margin
-951.72%
95.04%
-52.05%
-45.46%
Earnings per share
-
-
-
-
Interest and investment income
-
102.87M
-
-
Interest expense
-87.80M
-90.07M
-81.30M
-1.20M
Net interest expenses
-87.80M
12.80M
-81.30M
-1.20M
Depreciation and amortization charges
25.70M
22.96M
22.00M
22.00M
EBITDA
-570.75M
17.83B
-342.34M
-219.90M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps